Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Cuvier

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 25, 2015
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy RegimenDavid Groheux, Lucie Biard, Sylvie Giacchetti, et al.
Clinical Breast Cancer|June 22, 2021
Intraoperative Radiotherapy for Breast Cancer in Elderly WomenS Ophie Guillerm, Edwige Bourstyn, Ramona Itti, et al.
Reproductive Biomedicine Online|January 25, 2016
Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnanciesAnne-Sophie Hamy, Raphaël Porcher, Sarah Eskenazi, et al.
Clinical Breast Cancer|November 30, 2019
Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 PatientsBruno Cutuli, Claire Lemanski, Brigitte De Lafontan, et al.
Reproductive Biomedicine Online|September 24, 2014
Ovarian reserve in breast cancer: assessment with anti-Müllerian hormoneAnne-Sophie Hamy, Raphaël Porcher, Caroline Cuvier, et al.
International Journal of Radiation Oncology, Biology, Physics|April 26, 2008
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancerDavid Groheux, Jean-Luc Moretti, Georges Baillet, et al.
Cancer|March 19, 2013
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapyDavid Groheux, Mathieu Hatt, Elif Hindié, et al.
Cancer Medicine|August 29, 2025
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score AnalysisAurelia Robert, Paul Gougis, Elise Dumas, et al.
Cancers|September 22, 2020
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NACLuca Campedel, Paul Blanc-Durand, Asker Bin Asker, et al.
Breast Cancer Research : BCR|May 14, 2013
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15Jacqueline Lehmann-Che, Anne-Sophie Hamy, Raphaël Porcher, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 25, 2015
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy RegimenDavid Groheux, Lucie Biard, Sylvie Giacchetti, et al.
Clinical Breast Cancer|June 22, 2021
Intraoperative Radiotherapy for Breast Cancer in Elderly WomenS Ophie Guillerm, Edwige Bourstyn, Ramona Itti, et al.
Reproductive Biomedicine Online|January 25, 2016
Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnanciesAnne-Sophie Hamy, Raphaël Porcher, Sarah Eskenazi, et al.
Clinical Breast Cancer|November 30, 2019
Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 PatientsBruno Cutuli, Claire Lemanski, Brigitte De Lafontan, et al.
Reproductive Biomedicine Online|September 24, 2014
Ovarian reserve in breast cancer: assessment with anti-Müllerian hormoneAnne-Sophie Hamy, Raphaël Porcher, Caroline Cuvier, et al.
International Journal of Radiation Oncology, Biology, Physics|April 26, 2008
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancerDavid Groheux, Jean-Luc Moretti, Georges Baillet, et al.
Cancer|March 19, 2013
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapyDavid Groheux, Mathieu Hatt, Elif Hindié, et al.
Cancer Medicine|August 29, 2025
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score AnalysisAurelia Robert, Paul Gougis, Elise Dumas, et al.
Cancers|September 22, 2020
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NACLuca Campedel, Paul Blanc-Durand, Asker Bin Asker, et al.
Breast Cancer Research : BCR|May 14, 2013
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15Jacqueline Lehmann-Che, Anne-Sophie Hamy, Raphaël Porcher, et al.
Pageof 3